You are currently viewing Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead to just one facet of the potential patient access challenges for MDMA-assisted therapy; the second briefly covers comments and unpublished analysis shared by Rick Doblin; and, the third looks at synthetic vs. whole-mushroom psilocybin.

It also contains brief coverage of a number of other developments, including significant fundraising activity by MindMed and Cybin, as well as the launch of Usona Institute’s Phase 3 study…

Featured content in this Issue:

  • Looking Ahead at Patient Access to MDMA-Assisted Therapy
  • Rick Doblin on the ‘Future of Psychedelics’
  • Whole Mushroom vs. Synthetic Psilocybin
  • Usona Launches Phase 3 Study of Psilocybin for Major Depressive Disorder
  • MindMed and Cybin Attract Investors with Breakthrough Therapy Designations
  • Other News; In Case You Missed It

Companies, organisations and drug candidates mentioned in this Bulletin: Lykos Therapeutics, MDMA-assisted therapy; Usona Institute; MindMed; Cybin; CYB004.

PA+ Header Psychedelic Alpha

This content is for Pα+ Subscribers

This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Sign-in button

Join Button